STAT6 and solitary fibrous tumor: The NAB2-STAT6 gene fusion is considered to be the underlying mutation leading to STAT6 overexpression, which is currently recognized as the primary event in disease development as well as a specific immunohistochemical marker for the diagnosis of SFT [4].